肿瘤预防与治疗2024，Vol.37Issue(7)：563-570,8.DOI:10.3969/j.issn.1674-0904.2024.07.003
血浆外泌体PD-L1在ⅢB～Ⅳ期非小细胞肺癌患者中的应用
Application of Plasma Exosomal PD-L1 in Patients with Stage ⅢB-Ⅳ Non-Small Cell Lung Cancer
摘要
Abstract
Objective:To explore the application of plasma exosomal programmed death ligand-1(PD-L1)in patients with stage ⅢB-Ⅳ non-small cell lung cancer(NSCLC).Methods:Thirty-five newly diagnosed patients with stage ⅢB-ⅣNSCLC were selected.The expression of PD-L1 in tumor tissue sections was detected by immunohistochemistry(IHC),and the content of PD-L1 in peripheral venous blood was detected by kit.Furthermore,the correlation between exosomal PD-L1(Exo-PD-L1)expression level in plasma and PD-L1 expres-sion level in tumor tissue was analyzed,and the relationship between Exo-PD-L1 expression level in plasma and clinico-pathological features was analyzed.After anti-PD-1/PD-L1 im-munotherapy,the patients were evaluated by irRECIST every 3 months,and the objective response rate(ORR)and disease control rate(DCR)were calculated to explore the value of Exo-PD-L1 in predicting the response to immunotherapy.Results:Both tissue PD-L1 and Exo-PD-L1 were expressed in stage Ⅲ B-Ⅳ NSCLC patients.There was no significant difference be-tween positive/negative IHC PD-L1 expression and Exo-PD-L1 expression in advanced NSCLC patients(P=0.072).Chi-square test showed that there was no significant correlation between Exo-PD-L1 expression and IHC PD-L1 expression in NSCLC patients(P=0.086);and there was no significant correlation between Exo-PD-L1 expression and clinicopathological characteristics(age,sex,histological subtype and smoking history)in advanced NSCLC patients(P＞0.05).Conclusion:There was no significant correlation between IHC PD-L1 expression and Exo-PD-L1 expression in stage Ⅲ B-Ⅳ NSCLC pa-tients,indicating that the expression levels of IHC PD-L1 and Exo-PD-L1 in stage ⅢB-Ⅳ NSCLC patients were not consist-ent.The ORR and DCR of patients with high expression of Exo-PD-L1 were higher than those with low expression,indicating that Exo-PD-L1 can be used to predict the prognosis of patients with advanced NSCLC.关键词
非小细胞肺癌/血浆外泌体PD-L1/免疫治疗/客观缓解率/疾病控制率Key words
NSCLC/Exo-PD-L1/Immunotherapy/ORR/DCR分类
医药卫生引用本文复制引用
叶梦杰,经慧,武焱旻,陈兰新,高姗姗,刘树安,王慧,陈天恩..血浆外泌体PD-L1在ⅢB～Ⅳ期非小细胞肺癌患者中的应用[J].肿瘤预防与治疗,2024,37(7):563-570,8.基金项目
This study was supported by grants from Science and Technology Bureau of Xuzhou(No.KC21167).徐州市2021年推动科技创新项目(编号:KC21167) （No.KC21167）
